Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 14
2003 13
2004 10
2005 25
2006 7
2007 15
2008 21
2009 24
2010 36
2011 27
2012 44
2013 45
2014 48
2015 58
2016 45
2017 38
2018 57
2019 53
2020 35
2021 38
Text availability
Article attribute
Article type
Publication date

Search Results

563 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for ae yong kim
Search for Ae Young Kim instead (2 results)
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, Cho JY, Her AY, Cho S, Jeon DW, Yoo SY, Cho DK, Hong BK, Kwon H, Ahn CM, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y; TICO Investigators. Kim BK, et al. Among authors: kim yh. JAMA. 2020 Jun 16;323(23):2407-2416. doi: 10.1001/jama.2020.7580. JAMA. 2020. PMID: 32543684 Free PMC article. Clinical Trial.
OBJECTIVE: To determine whether switching to ticagrelor monotherapy after 3 months of DAPT reduces net adverse clinical events compared with ticagrelor-based 12-month DAPT in patients with ACS treated with drug-eluting stents. ...MAIN OUTCOMES AND MEASURES: The primary out …
OBJECTIVE: To determine whether switching to ticagrelor monotherapy after 3 months of DAPT reduces net adverse clinical events compar …
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Bang YJ, et al. Among authors: kim yh. Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7. Lancet. 2012. PMID: 22226517 Clinical Trial.
Median follow-up was 342 months (254-417) in the chemotherapy and surgery group and 343 months (256-419) in the surgery only group. 3 year disease-free survival was 74% (95% CI 69-79) in the chemotherapy and surgery group and 59% (53-64) in the surgery only group (hazard ratio 05 …
Median follow-up was 342 months (254-417) in the chemotherapy and surgery group and 343 months (256-419) in the surgery only group. 3 year d …
Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.
Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, Gifford K, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Klopp AH, et al. Among authors: kim yb. J Clin Oncol. 2018 Aug 20;36(24):2538-2544. doi: 10.1200/JCO.2017.77.4273. Epub 2018 Jul 10. J Clin Oncol. 2018. PMID: 29989857 Free PMC article. Clinical Trial.
Secondary end points included change in patient-reported urinary toxicity, change in GI toxicity measured with the Patient-Reported Outcome Common Terminology Criteria for Adverse Events, and quality of life measured with the Trial Outcome Index. ...
Secondary end points included change in patient-reported urinary toxicity, change in GI toxicity measured with the Patient-Reported Outcome …
Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study.
Lee SE, Chang HJ, Sung JM, Park HB, Heo R, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Lee BK, Chun EJ, Cademartiri F, Maffei E, Marques H, Leipsic JA, Shin S, Choi JH, Chinnaiyan K, Raff G, Virmani R, Samady H, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Min JK. Lee SE, et al. Among authors: kim yj. JACC Cardiovasc Imaging. 2018 Oct;11(10):1475-1484. doi: 10.1016/j.jcmg.2018.04.015. Epub 2018 Jun 13. JACC Cardiovasc Imaging. 2018. PMID: 29909109 Free article.
OBJECTIVES: This study sought to describe the impact of statins on individual coronary atherosclerotic plaques. BACKGROUND: Although statins reduce the risk of major adverse cardiovascular events, their long-term effects on coronary atherosclerosis remain unclear. . …
OBJECTIVES: This study sought to describe the impact of statins on individual coronary atherosclerotic plaques. BACKGROUND: Although statins …
Resolvin D3 controls mouse and human TRPV1-positive neurons and preclinical progression of psoriasis.
Lee SH, Tonello R, Im ST, Jeon H, Park J, Ford Z, Davidson S, Kim YH, Park CK, Berta T. Lee SH, et al. Among authors: kim yh. Theranostics. 2020 Oct 26;10(26):12111-12126. doi: 10.7150/thno.52135. eCollection 2020. Theranostics. 2020. PMID: 33204332 Free PMC article.
Despite an increasing availability of immune therapies, they often have adverse effects, high costs, and dissociated effects on inflammation and itch. ...Recent studies have demonstrated that resolvins, endogenous lipid mediators derived from omega-3 fatty ac …
Despite an increasing availability of immune therapies, they often have adverse effects, high costs, and dissociated effect
Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study.
Yeung AR, Pugh SL, Klopp AH, Gil KM, Wenzel L, Westin SN, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Deshmukh S, Bruner DW, Kachnic LA. Yeung AR, et al. Among authors: kim yb. J Clin Oncol. 2020 May 20;38(15):1685-1692. doi: 10.1200/JCO.19.02381. Epub 2020 Feb 19. J Clin Oncol. 2020. PMID: 32073955 Free PMC article. Clinical Trial.
PURPOSE: In oncology trials, the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) is the standard tool for reporting adverse events (AEs), but it may underreport symptoms experienced by patients. ...Patients reported high-grade abdomi …
PURPOSE: In oncology trials, the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) is the standard too …
Exogenous influences on intraocular pressure.
Kim YW, Park KH. Kim YW, et al. Br J Ophthalmol. 2019 Sep;103(9):1209-1216. doi: 10.1136/bjophthalmol-2018-313381. Epub 2019 Mar 25. Br J Ophthalmol. 2019. PMID: 30910873 Review.
Catheter-Related Bladder Discomfort: How Can We Manage It?
Jang EB, Hong SH, Kim KS, Park SY, Kim YT, Yoon YE, Moon HS. Jang EB, et al. Among authors: kim yt. Int Neurourol J. 2020 Dec;24(4):324-331. doi: 10.5213/inj.2040108.054. Epub 2020 Dec 31. Int Neurourol J. 2020. PMID: 33401353 Free PMC article.
The urethral catheter is used in various clinical situations such as diagnosing urologic disease, urine drainage in patients after surgery, and for patients who cannot urinate voluntarily. However, catheters can cause numerous adverse effects, such as catheter-assoc …
The urethral catheter is used in various clinical situations such as diagnosing urologic disease, urine drainage in patients after surgery, …
563 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page